- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Cases selected for the AskAnzal weekly PMCPA insight newsletter
A hospital doctor said an Imraldi mailing requiring a signature was harassment and an inappropriate marketing practice. Panel…
A senior employee’s LinkedIn comment praising Strivit D3 (“licensed, prescribed, kosher and halal”) was ruled to be public…
Complaint said an Ozempic promotional email implied use in all type 2 diabetes patients because “adults” appeared later…
Teva’s HCP and education websites were ruled promotional in parts. Breaches included missing prominent PI/AE signposting online, missing…
Bayer challenged Janssen’s Erleada promotional video alleging off-licence promotion and misleading/disparaging cross-trial safety comparisons. The PMCPA Panel ruled…
Complaint alleged LinkedIn promotion and breach of an undertaking by AstraZeneca. PMCPA concluded the matter was outwith the…
Daiichi Sankyo facilitated an AF digital diagnosis opinion article on an independent news site, but its involvement was…
Theramex’s LinkedIn ‘About Us’ described its solutions as “innovative, effective and safe”. The PMCPA ruled this was misleading…
A GP complained about an allegedly unsolicited promotional email for Actonel Combi. The Panel found the recipient had…
A Times diabetes supplement funded and editorially controlled by Novo Nordisk included trial claims about unapproved liraglutide. The…
One real case. One key lesson. Every week — free.